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We investigated whether preoperative levels of serum C-reactive protein (CRP) and its correlation with tumour clinicopathological
findings adds prognostic information beyond the time of diagnosis in patients with myeloma bone disease (MM) to facilitate the
surgical decision-making process. Six hundred and fifty-eight myeloma patients were evaluated retrospectively for surgery.
Clinicopathological variables of patients who underwent surgery (n¼71) were compared between patients with preoperative CRP
X6mgl
 1 and those with CRP o6mgl
 1. Univariate and multivariate analyses were performed to identify prognostic factors after
surgery. Patients with an increase of CRP prior to surgery showed inferior survival compared to patients with normal levels. Patients
with normal CRP levels at diagnosis but elevations prior to surgery do seem to have a similar unfavourable overall survival (OS) than
patients with an increase both, at diagnosis and at surgery. Conversely, patients with normal CRP levels prior to surgery still have the
best OS, irrespective of their basic values. Multivariate analysis revealed preoperative CRP levels above 6mgl
 1 Lactate
dehydrogenase (LDH) above normal, and osteolyses in long weight bearing bones as independent predictors of survival. These
findings suggest that in patients with MM serum levels of CRP increase during disease activity and might be significantly correlated with
specific disease characteristics including adverse prognostic features such as osteolyses in long weight bearing bones. Thus,
preoperative elevated CRP serum levels might be considered as independent predictor of prognosis and could provide additional
prognostic information for the risk stratification before surgical treatment in patients with myeloma bone disease.
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One of the most important clinical features of multiple myeloma
(MM) is the development of lytic bone lesions. Over 70% of
patients present with skeletal lesions at diagnosis (Berenson, 2005).
Besides systemic treatment, these patients frequently require local
radiotherapy, agents such as bisphosphonates, and long-term
analgesic medications. Surgery has a supportive role in the
management of myeloma and is performed with the intention to
surgically stabilise an impending or existing pathologic fracture or
an osteolytic deposit.
Although the outcome has improved with a median survival of
4–5 years since the introduction of high-dose therapy (HDT) with
peripheral blood stem cell transplantation (PBSCT) and new drugs
like Thalidomide and Bortezomib, aggressive features of myeloma
bone lesions have significantly contributed to a poor outcome
(Durie et al, 2003; Tricot et al, 2004; Morgan and Davies, 2005;
Rajkumar and Kyle, 2005; Glasmacher et al, 2006).
In general, the decision to proceed with surgery is complex and
depends on survival estimates based on established prognostic
factors and largely on the clinical status of the patient. For
example, in cases of vertebral fractures, for patients with a life
expectancy of only a few months, surgery is not mandatory in the
absence of neurological deficits, if advantages offered by other
forms of treatment exist. Therefore, for identifying those patients
at risk for early death and for selecting appropriate surgical
interventions if longer survival is expected, it would be extremely
valuable for orthopedic surgeons to find a marker of disease
aggressiveness at the time of surgery that is easy to asses. In
addition to the prognostic value of baseline biological markers
including high levels of b2-microglobulin (B2-M), lactate dehy-
drogenase (LDH), and serum albumin (Bataille et al, 1992),
elevations of serum C-reactive protein (CRP) have been consis-
tently associated with a poor prognosis in myeloma (Tienhaara
et al, 1994; Kaneko et al, 2002; Terpos et al, 2003). Several studies
regarding the role of preoperative CRP as a predictive indicator for
the malignant potential and prognosis in various other cancers
have been published (Nozoe et al, 1998; Nakanishi et al, 2002;
Shimada et al, 2003; Hashimoto et al, 2005). However, the
prognostic significance based on preoperative CRP has not been
clarified for myeloma patients, yet. Based on preliminary results
(Zeifang et al, 2005), our intention was to describe the surgical
outcome of patients with myeloma bone disease and to investigate
whether preoperative CRP levels and its correlation with tumour
clinicopathological findings add prognostic information to
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spatients with myeloma bone disease in order to facilitate the
surgical decision-making process.
METHODS
Patients
A total of 658 myeloma patients who were treated with high-dose
therapy (HDT) and autologous peripheral blood stem cell
transplantation (PBSCT) according to clinical trial protocols
(Goldschmidt, 2003) were reviewed retrospectively. Patients were
conditioned with either one (n¼199) or two courses of melphalan
200mgm
 2 (n¼379) or with a combination of melphalan
140mgm
 2 and total body irradiation (TBI) (n¼80). Eighty-four
patients (12.4%) underwent surgery for their osteolyses. Of these,
13 patients were treated according to clinical trial protocol with
melphalan 140mgm
 2 and TBI, 24 patients with a single course
melphalan 200mgm
 2, and 47 patients with two courses of
melphalan 200gm
 2. The complete and partial response rates were
29.6 and 70.4%. All patients received supportive care measures for
the treatment of anaemia and hypercalcaemia as well as long-term
bisphosphonate therapy. The state of disease prior to surgery was
retrospectively assessed.
The indication for surgical treatment at the extremities included
lesions with elevated fracture risk according to Mirels’ Scoring
System (Mirels, 1989) or pathological fractures. By definition an
impending pathological fracture risk (430%) is attributed to
scores of eight or higher. Indication for surgical intervention at the
vertebral column included progressive neurological impairment
according to the Grading System of Frankel (1969) assessing
sensory and motor function or severe vertebral body lesions.
Appropriate laboratory tests as well as a physical examination by
an internist, anaesthetist and the surgeon were routinely drawn
on the day before surgery for all patients in order to evaluate the
surgical risk and to identify patients with infections. Contra-
indications to surgery were any signs and symptoms of
preoperative infections.
The median age at the time of initial treatment was 55 years,
with a range of 30–70 years. Follow-up ranged from 8 to 179
months, with a median of 45 months. At the time of analysis, 29
patients (34.5%) had died.
Parameters
In addition to demographic data, the patients were assessed for
monoclonal protein isotypes, number and anatomic site of bone
lesions, state of disease prior to surgery, surgery prior to initial
treatment, and prior local radiation. Biochemical features prior to
surgery including CRP, B2-M, LDH, serum albumin, haemoglobin
and creatinine were collected from medical records. As elevations
of CRP above 6mgl
 1 may indicate a poorer prognosis, patients
with a rise of CRP above this level were assigned to the CRP
positive group.
Statistical analysis
Descriptive statistics were performed for all variables and
expressed as means7SD. Comparisons between the two groups
were calculated with the Mann–Whitney U-test for quantitative
data, with w
2 or fisher exact test for qualitative data. The end point
of interest was survival time, defined as the time from surgery to
death or last follow-up date. In addition to demographic data (age,
sex), independent variables consisted of clinical variables (number
and anatomical site of bone lesions) and medical variables
(tumour state prior to surgery, monoclonal protein isotypes,
preoperative CRP, LDH, haemoglobin and creatinine, prior local
radiation, and surgery prior to initial treatment). Normal serum
LDH was 100 to 190Ul
 1 for patients’ age p60 years and 110 to
210Ul
 1 for patients’ age 460 years.
The overall survival rates after surgery were calculated
according to Kaplan–Meier. Any significant differences were
determined with the log rank statistic. Univariate and multivariate
Cox stepwise proportional hazard models were used to identify
independent predictors of overall survival. Only those variables
found to be significant (Po0.10) in the univariate model were
entered into the multivariate model. A significance level of 0.10
was used for entry and retention of variables in the stepwise
multivariate model. P-values o0.05 were considered significant.
As the entire set of laboratory data was not available for 13
patients, those were excluded from this study. In total, 71 patients
with complete data were included in this retrospective analysis.
The statistical software used for the calculation was SPSS
(Standard Version 10.0, SPSS, Inc., Chicago, IL, USA).
RESULTS
Of 71 surgically treated patients with myeloma bone disease,
evaluated for CRP elevation prior to surgery, 26 (36.6%) were
assigned to the negative group and 45 (63.4%) to the positive
group. The median CRP levels were 2.7mgl
 1 (range 1.0–4.0) in
the negative group and 9.2mgl
 1 (range 6.0–76.4) in the positive
group, respectively. With an average of 13 months, the time
intervals between the diagnosis and surgery were higher for
patients with increased CRP levels compared to 6.2 months for
patients with normal values. The state of the disease prior to
surgery is shown in Table 1. While serum albumin and
haemoglobin levels in the CRP positive group were significantly
lower compared with the CRP negative group (P¼0.019 and
P¼0.055, respectively), B2-M, LDH and serum creatinine were
well balanced between the study groups (P¼0.678, P¼0.123, and
0.554, respectively). The key prognostic variables of the two groups
are summarised in Table 2.
Clinically relevant osteolytic lesions were located in the vertebral
column in 42 (59.2%), ribs in two (2.8%), proximal humerus in one
(1.4%), humerus shaft in eight (11.3%), proximal femur in seven
(9.9%), femur shaft in six (8.5%) and each one in the tibia shaft,
ulna shaft, cranial bone, clavicula and jaw, respectively.
Vertebral tumours were excised through anterior and/or
posterior approach, combined with a stabilising procedure in
41 (97.6%) cases, or kyphoplasty in one (2.4%) case. Either
intramedullary rod fixation (n¼16; 69.5%) or endoprosthesis
(n¼7; 30.5%) were inserted to give support for weight bearing
bones. Five tumours were excised through local tumour resection
without stabilisation. In all 25 patients (35.2%) underwent local
radiation prior to surgery. In 34 (47.9%) cases, orthopedic surgery
had to be performed before the onset of initial treatment. With
9.8% (7/71) the observed complication rate following surgery was
low. The median age at surgery was 56 years, with a range from
30 to 68 years. After a median follow-up of 57 months (4–132
months), 29 patients (40.8%) had died. The 1-, 3-, and 5-year OS
rates were 92.7, 62.1 and 47.9%, respectively. The peri- and
postoperative mortality rate within 30 postoperative days was zero
in this group.
Table 1 Patients’ state of disease prior to surgery
StateCriteria No. of patients (%)
1 Prior to HDT with PBSCT 59 (83.1)
2 After HDT with PBSCT in relapse 7 (9.9)
3 After HDT with PBSCT in remission 5 (7.0)
4 After HDT with PBSCT during treatment of relapse None
HDT¼high dose therapy; PBSCT¼peripheral blood stem cell transplantation.
Preoperative elevation of serum C
A Zahlten-Hinguranage et al
783
British Journal of Cancer (2006) 95(7), 782–787 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sOverall survival after surgery
Patients with a lower CRP level (o6mgl
 1) prior to surgery had a
better OS after surgical intervention with a median survival of 58.0
months than patients with a rise above this level (median survival
35.9 months) (P¼0.0046). Overall survival estimates at 1, 3 and 5
years were 100.0, 89.2 and 70.1%, respectively, vs 88.6, 48.0 and
36.4%, respectively (Figure 1).
Predictors of mortality
In univariate Cox analysis, significantly poorer predictive values
were found for or a rise of CRP X6mgl
 1 prior to surgery
(P¼0.008), LDH above normal (P¼0.027), serum creatinine
X2mgdl
 1 (P¼0.036), and lytic lesions in long weight bearing
bones (P¼0.001). Moreover, the state of disease prior to surgery
was found to have prognostic influence by univariate analysis, too
(P¼0.026). In particular, patients with HDT and PBSCT in relapse
prior to surgery were 3.3 times more likely to die than those
patients whose surgery was performed prior to systemic therapy.
Subsequent, surgery prior to initial treatment was found to be a
positive prognostic factor for survival in patients with myeloma
bone disease (P¼0.006). The prognostic value of each factor
analysed by univariate analysis is listed in Table 3.
The effect on survival of the dynamic of serum CRP over time
was evaluated (Table 4). Patients were classified according to their
CRP levels at diagnosis and at surgery. Survival was greater for
patients with normal preoperative CRP levels compared to those
patients with elevations irrespective of their initial CRP values
(P¼0.0446) (Figure 2).
The results of multivariate analysis using the stepwise Cox
proportional hazards regression model are shown in Table 5.
In particular, preoperative serum CRP levels above 6mgl
 1
(HR¼2.721; P¼0.048) and osteolyses in long weight bearing
bones (HR¼0.476; P¼0.058) remained as independent predictors
of mortality.
Table 2 Key prognostic variables in patients with elevations in c-reactive
protein (CRP) prior to surgery
Variable value
CRP o6mgl
 1
(n¼26)
CRP X6mgl
 1
(n¼45) P-value
Age (yrs) 53.578.4 54.779.5 0.572
Gender (male:female ratio) 17:9 27:18 0.653
X3 lytic lesions 18 (69.2%) 33 (73.3%) 0.711
M component type
Bence Jones or IgD 6 (23.1%) 16 (35.6%) 0.273
b2-Microglobulin (mgl
 1) 2.6871.4 2.5470.15 0.678
Serum albumin (gdl
 1) 39.275.8 35.875.9 0.019*
LDH (Ul
 1) 168.4748.1 192.4770.8 0.123
Hemoglobin (gdl
 1) 12.771.5 11.971.6 0.055*
Ca
2+ (mmoll
 1) 2.3570.2 2.4770.4 0.109
Serum creatinine (mgdl
 1) 0.8270.2 0.8670.3 0.554
Best response to HDT+PBSCT
Complete response (CR) 9 (34.6%) 12 (26.7%) 0.429
Partial response (PR) 17 (65.4%) 33 (73.3%) 0.480
Prior local radiation 6 (23.1%) 19 (42.2%) 0.104
Surgery prior to initial treatment 15 (57.7%) 19 (42.2%) 0.209
Osteolyses in long bones 6 (23.1%) 19 (42.2%) 0.104
Postoperative complications 2 (7.7%) 5 (11.1%) 0.642
Values shown are the mean7s.d.
*Statistically significant at the 0.05 level.
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Figure 1 Overall survival rates after surgery were significantly higher for
patients with a CRP level o6mgl
 1 prior to surgery compared to patients
with CRP 46mgl
 1 (P¼0.0046).
Table 3 Hazard ratios from the univariate Cox PH model for surgically treated patients with myeloma bone disease
Covariate Coefficient (bi) HR [exp(bi)] 95% CI P-value
Age 0.001 1.001 0.96–1.04 0.949
Gender 0.146 1.158 0.54–2.50 0.709
Preoperative CRP (o6 vs X6mgl
 1) 1.305 3.687 1.40–9.70 0.008*
X3 lytic lesions 0.070 1.073 0.48–2.42 0.866
Bence Jones or IgD 1.175 1.191 0.95–1.48 0.124
State of disease prior to operation 0.026*
Before HDT and PBSCT
In relapse 1.205 3.337 1.33–8.37 0.010*
In remission  0.599 0.550 0.74–4.09 0.559
b2-Microglobulin (o3.5 vs 43.5gdl
 1)  0.988 0.372 0.09–1.57 0.178
LDH (above normal vs normal) 0.824 2.280 1.09–4.73 0.027*
Anaemia (Hb o10 vs X10gdl
 1) 0.399 1.491 0.35–6.39 0.590
Serum creatinine (X2 vs o2mgdl
 1) 2.266 9.644 1.16–80.1 0.036*
Serum albumin (o3.5 vs X3.5mgl
 1) 0.455 1.577 0.75–3.31 0.228
Prior local radiation (yes vs no) 0.312 1.367 0.65–2.87 0.408
Surgery prior to initial treatment (yes vs no)  1.105 0.331 0.15–0.73 0.006*
Osteolyses in long bones (yes vs no) 1.195 3.303 1.59–6.89 0.001*
HDT¼high dose therapy; PBSCT¼peripheral blood stem cell transplantation.
*Pp0.05.
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Although elevations of C-reactive protein (CRP) serum levels in
newly diagnosed patients with myeloma bone disease have been
consistently associated with a poor prognosis (Bataille et al, 1992;
Tienhaara et al, 1994; Durie et al, 2003) the significance of
preoperative CRP levels have not been clarified as of prognostic
importance in myeloma patients, yet, and was, for the first time,
subject of this study.
The major finding of this investigation is the inferior survival of
patients with myeloma bone disease in whom CRP was elevated
prior to surgery. This result replicates that of previous research
regarding the role of CRP as a predictive indicator for the
malignant potential and prognosis in various other cancers and
suggests several possibilities: (1) preoperative elevations of CRP
indicate a poor outcome in myeloma patients, or (2) bone
involvement needing surgery is a significant adverse factor.
Alterations of serum CRP is a common feature in patients with
malignancies which has been found to be adversely prognostic,
with patients having elevated CRP levels (Nozoe et al, 1998;
Nakanishi et al, 2002; Shimada et al, 2003; Hashimoto et al, 2005).
Growing evidence suggests prognostic importance because in-
creased CRP levels are associated with the production of cytokines
from tumour cells (Kurzrock, 1997; Legouffe et al, 1998,
Yamamura et al, 1998). For myeloma it is well known that
interleukin-6 (IL-6) plays a crucial role in the cytokine network,
regulating the growth and survival of myeloma cells and
stimulating the acute-phase protein synthesis, notably C-reactive
protein (CRP) (Lauta, 2003). Several authors investigating serum
IL-6 in relation to acute-phase reactants and survival in myeloma
patients report not only significantly shorter survival for those
with higher concentrations of IL-6 compared with patients who
had normal concentrations (Ludwig et al, 1991; Pulkki et al, 1996;
Papadaki et al, 1997; Stasi et al, 1998), but also demonstrate a
strong positive correlation between IL-6 and CRP (Tienhaara et al,
1994; Pelliniemi et al, 1995; Kyriakou et al, 1997; Biro et al, 1998;
Alexandrakis et al, 2003). As an assessment of infection status at
the time of surgery was made, CRP rather appears to act as a
surrogate marker for IL-6 activity and proliferative status of bone
marrow plasma cells and has been regarded as a powerful
prognostic marker in patients with multiple myeloma, than a sign
for preoperative infectious states.
Our results extend previous observations regarding the role of
CRP as an independent prognostic marker in multiple myeloma,
indicating that CRP has predictive power for patients with
myeloma beyond the time of diagnosis. In the present study it
could be shown that a raised preoperative CRP concentration was
strongly associated with a shorter survival. Patients with elevated
CRP levels were 2.72 times more likely to die than patients with
normal values. This difference in survival cannot be attributed to
response to HDT and PBSCT as the best response rates were
similar in both groups. Moreover, the different states of disease
prior to surgery failed to remain prognostic significant in
multivariate analysis. Although the small number of cases
precludes definitive conclusion, it could be demonstrated that
patients with normal CRP levels at diagnosis but elevations prior
to surgery do seem to have a similar unfavourable overall survival
than patients with an increase both, at diagnosis and at surgery.
Conversely, in this study population, patients with normal CRP
levels prior to surgery had the best overall survival, irrespective of
their basic values.
Besides a relation with inferior survival, the current data
further showed that the serum CRP levels were inversely correlated
with serum albumin. This specific feature of high-serum
CRP concentration and hypoalbuminemia in some myeloma
patients has been addressed earlier with regard to disease
activity (Alexandrakis et al, 2003; Durie et al, 2003). In contrast
to high preoperative CRP levels, we did not find B2-microglobulin
as predictive parameter. B2-microglobulin is considered to
reflect the tumour load. We hypothesise that in this subgroup
of MM patients with clinically relevant osteolytic lesions, a high
tumour load can be assumed anyway, while the malignant
potential is better indicated by CRP as surrogate marker for
IL-6 levels.
Moreover, while B2M is a dominant prognostic factor for
survival at diagnosis, its prognostic relevance has not been shown
during the course of the disease, yet (San Miguel et al, 2004). On
the other hand, in accordance with the literature (Nachbaur et al,
1991; Pelliniemi et al, 1995) preoperative CRP concentrations were
Table 4 Effect of dynamics in CRP
Group No. of patients No. of patients alive Median survival (months) CI months
A Normal CRP at diagnosis and at surgery 21 17 NA
a NA
B Elevated CRP at diagnosis but normal at surgery 5 4 NA
a NA
C Normal CRP at diagnosis but elevated at surgery 20 9 39.9 13.1–66.7
D Elevated CRP at diagnosis and at surgery 25 12 35.9 22.4–49.4
aNot available.
1.0
0.9
0.8
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
01 2 2 4 3 64 86 0
Group C
Group D
Group A
Group B
Survival after surgery (months)
C
u
m
 
s
u
r
v
i
v
a
l
Figure 2 Overall survival rates after surgery per rise of CRP. Number of
patients: Group A¼21; Group B¼5; Group C¼20; Group D¼25.
Table 5 Hazard ratios from the multivariate Cox PH model for surgically
treated patients with myeloma bone disease
Covariate
Coefficient
(bi)
HR
[exp(bi)]
95%
CI P-value
Preoperative CRP
(o6 vs X6mgl
 1)
1.001 2.721 1.01–7.33 0.048
Osteolyses in long bones  0.742 0.476 0.22–1.03 0.058
Preoperative elevation of serum C
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variables of the disease, haemoglobin level. Consistent with
previous reports (Hannisdal et al, 1990; Zeifang et al, 2005), lytic
bone lesions were found to be important for prognosis if they were
located in the long bones, too. It is reasonable to assume that bone
involvement needing surgery might be a significant adverse factor
since myeloma cells first expand in the bone marrow infiltrating
the axial skeleton, and with increased cellular proliferation they
cause extensive bone destruction and osteolyses in long weight
bearing bones. The higher time intervals between the diagnosis
and surgery for patients with increased CRP levels might support
this hypothesis. However, based on the total of 658 myeloma
patients, the 1-, 3- and 5-year OS estimates from diagnosis were
98.3, 83.9 and 65.0% for patients without surgery and 98.5, 78.0
and 55.4%, respectively, for patients undergoing surgical inter-
vention. When stratified for serum CRP concentration patients
with lytic lesions in the long bones had significantly lower 1- and
3-year overall survival estimates with preoperatively increased
CRP levels than patients with normal values (75.3 and 21.9 vs 100.0
and 75.0%, respectively). This provides additional evidence that
more or less aggressive features of myeloma bone lesions exists.
However, the underlying molecular mechanism of bone destruc-
tion and tumour progression is still a field of extensive research
and essential for the interpretation of this adverse prognostic
feature. Nevertheless, taken into account the higher portion of
patients requiring prior radiotherapy and osteolyses in long bones,
despite inferior survival surgery is still needed in patients with
myeloma bone disease, even with high CRP levels, to stabilise an
impending or existing pathological fracture, or to excise an
osteolytic deposit as an adjunct to chemotherapy and mainly for
symptom control.
CONCLUSION
Taken together, these findings suggest that in patients with
multiple myeloma, serum levels of CRP increase during disease
activity and might be significantly correlated with specific disease
characteristics including adverse prognostic features such as
osteolyses in long weight bearing bones. Thus, preoperative
elevated CRP serum levels should be considered as an independent
predictor of prognosis beyond diagnosis and might provide
additional prognostic information for the risk stratification before
surgical treatment in patients with myeloma bone disease.
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